Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

14.35B

Market cap14.35B

Price-Earnings ratio

18.60

Price-Earnings ratio18.60

Dividend yield

—

Dividend yield—

Average volume

2.98M

Average volume2.98M

High today

$57.42

High today$57.42

Low today

$56.01

Low today$56.01

Open price

$56.02

Open price$56.02

Volume

2.11M

Volume2.11M

52 Week high

$57.57

52 Week high$57.57

52 Week low

$33.76

52 Week low$33.76

Stock Snapshot

Exelixis(EXEL) stock is priced at $57.10, giving the company a market capitalization of 14.35B. It carries a P/E multiple of 18.60.

On 2026-07-09, Exelixis(EXEL) stock moved within a range of $56.01 to $57.42. With shares now at $57.10, the stock is trading +1.9% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 2.11M, compared to an average daily volume of 2.98M.

The stock's 52-week range extends from a low of $33.76 to a high of $57.57.

EXEL News

Nasdaq 6h

Here's Why Exelixis is a Strong Growth Stock

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Z...

TipRanks 2d

Exelixis price target raised to $56 from $54 at Truist

Truist raised the firm’s price target on Exelixis (EXEL) to $56 from $54 and keeps a Hold rating on the shares as part of a broader research note updating the f...

Simply Wall St 4d

Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis

In late June 2026, Exelixis, Inc. was removed from three Russell 1000 Defensive-style indexes just as it reported final subgroup overall survival results from i...

Analyst ratings

50%

of 20 ratings

Buy

40%

Hold

50%

Sell

10%

More EXEL News

Simply Wall St 5d

Is Exelixis Undervalued Or Already Priced In On Its Oncology Growth Story?

Exelixis (EXEL) has come back into focus after being removed from several Russell 1000 defensive style indices. This shift may influence how some quantitative a...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.